Overcoming the hurdles of immune cell therapy analysis

With ongoing scientific and technological advances revolutionizing the landscape of immune cell therapy, the quick growth of the industry has introduced notable challenges and bottlenecks for developers and manufacturers. These challenges include scalability, regulatory hurdles, and standardization of data.

In this webinar, a panel of industry experts will discuss these issues, along with rising trends and innovative analytical methods in the development and evaluation of immune cell therapy.

Discussion topics

• The influence of automation on manufacturers of immune cell therapy
• Reconsideration of conventional approaches to decrease bias and errors in analytical assays
• The difficulties of expanding immune cell therapy beyond blood cancers
• Comparison of viral and non-viral methods in gene editing of immune cells
• The emergence of closed-system cell manufacturing platforms

Panelists

• Juan F. Vera, President & CEO, Marker Therapeutics
• Andrew Greenwald, Scientist, Genezen Laboratories
• Mitchell Ambrosino, Senior Associate Scientist, Be Biopharma
• David Hermanson, Director, Cell & Gene Therapy Applications, Bio-Techne

Moderator

Nathan Allen, Director, Product Marketing Management, Cell & Gene Therapy, Bio-Techne